Achieve Life Sciences (ACHV) Research & Development (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Research & Development came in at $3.0 million in Q1 2026, down 58.08% YoY from $7.1 million in Q1 2025, and down 22.53% on a QoQ basis from $3.8 million in Q4 2025.
Achieve Life Sciences (ACHV) Research & Development (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Research & Development data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Research & Development fell 58.08% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (down 30.51% YoY) and the FY2025 annual result came in at $23.0 million, up 0.64% from the prior year.
- Research & Development eased to $3.0 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.9 million in Q3 2022 to a low of $2.1 million in Q4 2023.
- A 5-year average of $5.6 million and a median of $5.3 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 75.46% — and 2024, when it surged 245.13%.
- Tracing ACHV's Research & Development over 5 years: stood at $8.6 million in 2022, then plunged by 75.46% to $2.1 million in 2023, then surged by 245.13% to $7.3 million in 2024, then slumped by 47.37% to $3.8 million in 2025, then dropped by 22.53% to $3.0 million in 2026.
- The last three Research & Development figures came in at $3.0 million (Q1 2026), $3.8 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 3.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.39 Mn |
| Mar 31, 2026 | 2.98 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 6.71 Mn |
| Mar 31, 2025 | 7.10 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 7.61 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Sep 30, 2022 | 9.87 Mn |
| Jun 30, 2022 | 7.21 Mn |
| Mar 31, 2022 | 4.39 Mn |
| Dec 31, 2021 | 4.51 Mn |
| Sep 30, 2021 | 4.59 Mn |